Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders

Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This revi...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2012-07, Vol.32 (7), p.2471-2478
Main Authors: ROGOSNITZKY, Moshe, DANKS, Rachel, KARDASH, Elena
Format: Article
Language:English
Subjects:
Adult
Animals
Anti-Allergic Agents - pharmacology
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Line, Tumor
Clinical Trials as Topic
Dermatology
Female
Humans
Medical sciences
Neoplasms - drug therapy
ortho-Aminobenzoates - pharmacology
ortho-Aminobenzoates - therapeutic use
Skin involvement in other diseases. Miscellaneous. General aspects
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid; Rizaben®) is an anti-allergy drug approved for use in Japan and South Korea, also used against asthma, autoimmune diseases, and atopic and fibrotic pathologies. The antitumor potential of tranilast is attracting considerable interest. This review summarizes recent evidence concerning the effect of tranilast on different tumor types and discusses the drug's possible mode of action in this area. In vivo and in vitro studies are covered, as well as evidence from clinical trials, in which tranilast was evaluated in various models of proliferative disorders. The findings presented in this report, demonstrate the excellent potential of tranilast in the management of certain types of tumor, and provide a strong rationale for the initiation of controlled clinical trials in this area.
ISSN:0250-7005
1791-7530